In an interview with the Greater Geneva Bern area (GGBa) Invest Western Switzerland, Professor Li Tang, co-founder of Leman Biotech, spoke about the reasons behind the company's decision to establish a subsidiary in Switzerland. He shared advice for Chinese enterprises considering investing in Switzerland, highlighting the advantages of Switzerland's geographical location and its renowned universities such as the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Swiss Federal Institute of Technology in Zurich (ETH), which provide a rich pool of biotechnology talent.
Professor Tang also mentioned that Switzerland has one of the fastest drug registration processes in the world, and has a thriving entrepreneurial and innovative environment, making it an ideal market for testing and selling new drugs. He emphasized that the establishment of Leman Biotech Lausanne SA in Lausanne, Switzerland represents a significant milestone for the company, enabling it to conduct multi-center clinical research on a global scale, which will further advance Leman Biotech's clinical research efforts.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
